Raloxifene prevents the growth of uterine leiomyomas in premenopausal women

Jirecek, Stefan; Lee, Andreas; Pávó, Imre; Crans, Gerald; Eppel, Wolfgang; Wenzl, René

doi:10.1016/j.fertnstert.2003.06.009

Cited by 56 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(WMD) 95% C.I being -22.20 (-42.20 to -2.20) was achieved [27]. This was possibly because the study group involved premenopausal subjects i.e.…”

Section: Discussionmentioning

confidence: 97%

Evaluation of the SERM Ormeloxifene in the Treatment of Uterine Fibroid in the Reproductive Age Group

2016

J Syndr

View full text Add to dashboard Cite

Background: The search for the ideal drug for medical treatment of fibroids is on. SERMs appear to be novel agents for hormonal manipulations. Ormeloxifene with biweekly dosing and minimum side effects needs evaluation for the above. Method:The study was a prospective clinical observation undertaken to evaluate the efficacy of ormeloxifene in uterine fibroid in reproductive age group. Forty four (44) women aged 20-50 year age group who attended the outpatient gynaecology department, diagnosed with fibroid uterus; symptomatic or asymptomatic were recruited for the study. Ormeloxifene 60 mg was given orally twice a week for 6 months. Follow up was done at monthly interval and at the end of 6 months clinically and by USG. The primary outcome measures were fibroid size, uterine size and delta size. Secondary outcomes were measurement of menstrual blood loss using the PBAC score, hemoglobin concentration and endometrial thickness. Results:No significant changes were observed in the leiomyoma, uterine and delta size. 90.9% fibroids remained unchanged at the end of 6 months. The difference in mean hemoglobin concentration, PBAC scores and endometrial thickness were statistically significant (p<0.001). Hysterectomy was required in 5(11.36%) cases. Conclusion:Ormeloxifene does not reduce fibroid size but prevents further growth of the tumour and significantly reduces menstrual blood loss in standard doses with minimum side effects for a short period of time.

show abstract

“…(WMD) 95% C.I being -22.20 (-42.20 to -2.20) was achieved [27]. This was possibly because the study group involved premenopausal subjects i.e.…”

Section: Discussionmentioning

confidence: 97%

Evaluation of the SERM Ormeloxifene in the Treatment of Uterine Fibroid in the Reproductive Age Group

2016

J Syndr

View full text Add to dashboard Cite

show abstract

“…Raloxifene has been found to reduce the volume of the uterus and fibroids in postmenopausal women. Its effect in premenopausal women is dose-dependent; it does not always reduce the size of fibroids [24,25,47].…”

Section: Selective Estrogen Receptor Modulatorsmentioning

confidence: 99%

Medical Management of Uterine Fibroids

Parsanezhad

Jahromi

2012

Curr Obstet Gynecol Rep

View full text Add to dashboard Cite

Uterine leiomyomas are the most common benign tumors of the uterus. Though benign, they can affect the quality of life for many women. Compared with the standard surgical treatments, medical therapy is attractive and avoids possible surgery-related complications. No medical therapy currently exists that can induce rapid regression of the myoma and symptoms with minimal side effects without affecting fertility. This review evaluates medical treatments that are currently available for the treatment of uterine fibroids.

show abstract

“…L'étude de Jirecek et al [69] a inclus 25 patientes porteuses d'utérus fibromateux et asymptomatiques. Les patientes étaient randomisées entre traitement par raloxifène à la dose de 180 mg par jour trois mois et abstention.…”

Section: Anti-estrogènes Ouunclassified